thalidomide has been researched along with Bowel Diseases, Inflammatory in 34 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide has anti-inflammatory and anti-angiogenetic activity that makes it suitable for treating inflammatory bowel diseases (IBD)." | 8.91 | The clinical implications of thalidomide in inflammatory bowel diseases. ( Bracci, F; Capriati, T; Corsetti, T; Diamanti, A; Elia, D; Knafelz, D; Papadatou, B; Torre, G, 2015) |
| "Thalidomide was effective in the management of TNBS-induced colitis in young rats." | 7.80 | Efficacy of thalidomide on trinitrobenzene sulfonate-induced colitis in young rats and its mechanism. ( Huang, Y; Liang, Y; Xu, J; Zheng, C, 2014) |
| " Upon repeated dosing of Thali@PDA for one week, symptoms of IBD in mice were significantly relieved, and histomorphology of the colitis colons were normalized." | 5.91 | Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects. ( Bai, Y; Fang, X; Fu, B; Huang, H; Li, X; Ma, C; Meng, Z; Miao, W; Ren, H; Shen, S; Tao, X; Wang, Y; Xu, H; Xu, Y; Yang, J; Yang, Z; Yong, J, 2023) |
| "Eleven patients (nine males, mean age 33 years, range 20-77 years) with chronic inflammatory bowel disease (six Crohn's disease (CD), four ulcerative colitis (UC), one indeterminate colitis (IC)) who were symptomatic despite standard medical therapy were administered a daily dose of thalidomide for 12 weeks in an open-labeled protocol." | 5.10 | Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. ( Bariol, C; Byrnes, DJ; Edwards, PD; Field, A; Hing, M; Meagher, AP; Vickers, CR; Wettstein, AR, 2002) |
| "Existing evidence suggests that thalidomide may be a valid treatment option for patients with inflammatory bowel diseases refractory to other first- and second-line treatments." | 4.93 | Thalidomide for inflammatory bowel disease: Systematic review. ( Bramuzzo, M; Lazzerini, M; Martelossi, S; Ventura, A, 2016) |
| "Thalidomide has anti-inflammatory and anti-angiogenetic activity that makes it suitable for treating inflammatory bowel diseases (IBD)." | 4.91 | The clinical implications of thalidomide in inflammatory bowel diseases. ( Bracci, F; Capriati, T; Corsetti, T; Diamanti, A; Elia, D; Knafelz, D; Papadatou, B; Torre, G, 2015) |
| " The efficacy and safety evaluations of several PDE4 inhibitors are currently carried on in clinical trials, for example GSK256066 in asthma, roflumilast and GSK256066 in chronic obstructive pulmonary disease, tetomilast in inflammatory bowel disease, and apremilast in dermatitis and arthritis etc." | 4.90 | [Progress in PDE4 targeted therapy for inflammatory diseases]. ( Song, SD; Tang, HF, 2014) |
| "Thalidomide was effective in the management of TNBS-induced colitis in young rats." | 3.80 | Efficacy of thalidomide on trinitrobenzene sulfonate-induced colitis in young rats and its mechanism. ( Huang, Y; Liang, Y; Xu, J; Zheng, C, 2014) |
| " Established risk factors in IBD colitis inpatients with TE included: indwelling catheter (4/10), first-degree family member with TE (2/10), hereditary thrombophilia (3/10), smoking (1/10), oral contraceptive (1/5 females), and thalidomide (1/10)." | 3.79 | Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. ( Atkinson, BJ; Bousvaros, A; Harney, KM; Levine, AE; Lightdale, JR; Trenor, CC; Verhave, M; Zitomersky, NL, 2013) |
| "Our results indicate that thalidomide can be an efficacious medication in appropriately selected patients with some inflammatory bowel diseases with many chances of success." | 3.74 | Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease. ( Akazawa, Y; Amano, Y; Minami, I; Nakamura, S; Uchida, N; Yamazaki, T; Yasui, K, 2008) |
| "Many treatments for psoriasis and psoriatic arthritis are also used for IBD." | 2.58 | Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. ( Armstrong, AW; Enos, CW; Gottlieb, A; Langley, RG; Lebwohl, M; Merola, JF; Ryan, C; Siegel, MP; Van Voorhees, AS; Weinberg, JM; Whitlock, SM; Wu, JJ, 2018) |
| "Although peripheral neuropathies in children are often of genetic origin, acquired causes should be carefully looked for and ruled out also in the pediatric age." | 2.58 | Peripheral neuropathy and gastroenterologic disorders: an overview on an underrecognized association. ( De' Angelis, GL; Di Mario, F; Fusco, C; Gaiani, F; Leandro, G; Pisani, F; Spagnoli, C, 2018) |
| " Upon repeated dosing of Thali@PDA for one week, symptoms of IBD in mice were significantly relieved, and histomorphology of the colitis colons were normalized." | 1.91 | Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects. ( Bai, Y; Fang, X; Fu, B; Huang, H; Li, X; Ma, C; Meng, Z; Miao, W; Ren, H; Shen, S; Tao, X; Wang, Y; Xu, H; Xu, Y; Yang, J; Yang, Z; Yong, J, 2023) |
| "Thalidomide has emerged as an effective immunomodulator in the treatment of pediatric patients with inflammatory bowel disease (IBD) refractory to standard therapies." | 1.91 | Gene expression profiling in white blood cells reveals new insights into the molecular mechanisms of thalidomide in children with inflammatory bowel disease. ( Bidoli, C; Bramuzzo, M; Brumatti, LV; Celsi, F; Curci, D; Decorti, G; Edomi, P; Gerdol, M; Lega, S; Licastro, D; Lionetti, P; Lucafò, M; Maestro, A; Nonnis, M; Paci, M; Pallavicini, A; Pugnetti, L; Renzo, S; Stocco, G, 2023) |
| "One hundred four patients (40." | 1.62 | Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs. ( Andriulli, A; Bossa, F; Carparelli, S; Corritore, G; D'Altilia, M; Guerra, M; Latiano, A; Latiano, T; Marseglia, A; Martino, G; Nardella, M; Palmieri, O; Panza, A; Pastore, M; Perri, F; Sacco, M; Tavano, F; Terracciano, F, 2021) |
| "Thalidomide is an effective therapy in children with inflammatory bowel disease refractory to standard treatments, but thalidomide-induced peripheral neuropathy (TiPN) limits its long-term use." | 1.46 | Risk Factors and Outcomes of Thalidomide-induced Peripheral Neuropathy in a Pediatric Inflammatory Bowel Disease Cohort. ( Arrigo, S; Barp, J; Bramuzzo, M; Calvi, A; Carrozzi, M; Chicco, A; Costa, S; Decorti, G; Di Chio, T; Fontana, M; Ghione, S; Lanteri, P; Lazzerini, M; Lionetti, P; Lucafò, M; Magazzù, G; Maggiore, G; Martelossi, S; Montico, M; Pellegrin, MC; Pellegrino, S; Stocco, G; Udina, C; Ventura, A; Zuin, G, 2017) |
| "Thalidomide is an immunomodulatory drug (IMiD) with proven therapeutic action in several autoimmune/inflammatory diseases; however, its inherent high toxicity has led to the development of more powerful and safer thalidomide analogs, including lenalidomide and pomalidomide." | 1.46 | Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. ( Criado, G; Delgado, M; Diaz de la Guardia, R; García-Herrero, CM; Gonzalez-Rey, E; Lavoie, JR; Lopez-Millan, B; Menendez, P; O'Valle, F; Roca-Ho, H; Rosu-Myles, M, 2017) |
| "Treatment with thalidomide restored malondialdehyde as well as reduction of myeloperoxidase and tumour necrosis factor-alpha towards normal levels." | 1.35 | Effect of different doses of thalidomide in experimentally induced inflammatory bowel disease in rats. ( Medhi, B; Pandhi, P; Prakash, O; Saikia, UN, 2008) |
| "Thalidomide pretreatment did not affect NF-kappaB activity in HT-29 cells stimulated with LPS but production of TNF-alpha was depressed." | 1.32 | The effects of thalidomide on the stimulation of NF-kappaB activity and TNF-alpha production by lipopolysaccharide in a human colonic epithelial cell line. ( Jung, HC; Kim, JS; Kim, YS; Song, IS, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (32.35) | 29.6817 |
| 2010's | 16 (47.06) | 24.3611 |
| 2020's | 7 (20.59) | 2.80 |
| Authors | Studies |
|---|---|
| Meng, Z | 3 |
| Fu, B | 3 |
| Yang, Z | 3 |
| Xu, Y | 3 |
| Huang, H | 3 |
| Bai, Y | 3 |
| Fang, X | 3 |
| Shen, S | 3 |
| Yang, J | 3 |
| Yong, J | 3 |
| Tao, X | 3 |
| Ma, C | 3 |
| Miao, W | 3 |
| Ren, H | 3 |
| Wang, Y | 3 |
| Xu, H | 3 |
| Li, X | 3 |
| Guo, L | 1 |
| Liu, Y | 1 |
| Li, J | 1 |
| Liu, Q | 1 |
| Liu, B | 1 |
| Shi, X | 1 |
| Pugnetti, L | 1 |
| Curci, D | 1 |
| Bidoli, C | 1 |
| Gerdol, M | 1 |
| Celsi, F | 1 |
| Renzo, S | 1 |
| Paci, M | 1 |
| Lega, S | 1 |
| Nonnis, M | 1 |
| Maestro, A | 1 |
| Brumatti, LV | 1 |
| Lionetti, P | 3 |
| Pallavicini, A | 1 |
| Licastro, D | 1 |
| Edomi, P | 1 |
| Decorti, G | 3 |
| Stocco, G | 2 |
| Lucafò, M | 2 |
| Bramuzzo, M | 4 |
| Foulon, A | 1 |
| Chevreau, J | 1 |
| Yzet, C | 1 |
| Gondry, J | 1 |
| Fumery, M | 1 |
| Marafini, I | 1 |
| Troncone, E | 1 |
| Salvatori, S | 1 |
| Monteleone, G | 1 |
| Bossa, F | 1 |
| Carparelli, S | 1 |
| Latiano, A | 1 |
| Palmieri, O | 1 |
| Tavano, F | 1 |
| Panza, A | 1 |
| Pastore, M | 1 |
| Marseglia, A | 1 |
| D'Altilia, M | 1 |
| Latiano, T | 1 |
| Corritore, G | 1 |
| Martino, G | 1 |
| Nardella, M | 1 |
| Guerra, M | 1 |
| Terracciano, F | 1 |
| Sacco, M | 1 |
| Perri, F | 1 |
| Andriulli, A | 1 |
| Penso, L | 1 |
| Bergqvist, C | 1 |
| Meyer, A | 1 |
| Herlemont, P | 1 |
| Weill, A | 1 |
| Zureik, M | 1 |
| Dray-Spira, R | 1 |
| Sbidian, E | 1 |
| Peng, X | 1 |
| Zhi, M | 1 |
| Wei, M | 1 |
| Li, TT | 1 |
| Zhang, M | 1 |
| Zhang, YQ | 1 |
| He, H | 1 |
| Su, M | 1 |
| Wang, W | 1 |
| Chen, JR | 1 |
| Tang, J | 1 |
| Gao, X | 1 |
| Hu, PJ | 1 |
| Liang, XY | 1 |
| Spadaccini, M | 1 |
| D'Alessio, S | 1 |
| Peyrin-Biroulet, L | 1 |
| Danese, S | 1 |
| Montico, M | 2 |
| Arrigo, S | 2 |
| Calvi, A | 2 |
| Lanteri, P | 1 |
| Costa, S | 1 |
| Pellegrino, S | 2 |
| Magazzù, G | 2 |
| Barp, J | 1 |
| Ghione, S | 1 |
| Zuin, G | 2 |
| Fontana, M | 2 |
| Di Chio, T | 1 |
| Maggiore, G | 2 |
| Lazzerini, M | 4 |
| Udina, C | 1 |
| Pellegrin, MC | 2 |
| Chicco, A | 1 |
| Carrozzi, M | 1 |
| Ventura, A | 4 |
| Martelossi, S | 3 |
| Whitlock, SM | 1 |
| Enos, CW | 1 |
| Armstrong, AW | 1 |
| Gottlieb, A | 1 |
| Langley, RG | 1 |
| Lebwohl, M | 1 |
| Merola, JF | 1 |
| Ryan, C | 1 |
| Siegel, MP | 1 |
| Weinberg, JM | 1 |
| Wu, JJ | 1 |
| Van Voorhees, AS | 1 |
| Spagnoli, C | 1 |
| Pisani, F | 1 |
| Di Mario, F | 1 |
| Leandro, G | 1 |
| Gaiani, F | 1 |
| De' Angelis, GL | 1 |
| Fusco, C | 1 |
| Zitomersky, NL | 1 |
| Levine, AE | 1 |
| Atkinson, BJ | 1 |
| Harney, KM | 1 |
| Verhave, M | 1 |
| Bousvaros, A | 1 |
| Lightdale, JR | 1 |
| Trenor, CC | 1 |
| Xu, J | 1 |
| Zheng, C | 1 |
| Huang, Y | 1 |
| Liang, Y | 1 |
| Song, SD | 1 |
| Tang, HF | 1 |
| Cozzani, E | 1 |
| Gasparini, G | 1 |
| Parodi, A | 1 |
| Yang, C | 1 |
| Singh, P | 1 |
| Singh, H | 1 |
| Le, ML | 1 |
| El-Matary, W | 1 |
| Diamanti, A | 1 |
| Capriati, T | 1 |
| Papadatou, B | 1 |
| Knafelz, D | 1 |
| Bracci, F | 1 |
| Corsetti, T | 1 |
| Elia, D | 1 |
| Torre, G | 1 |
| Lopez-Millan, B | 1 |
| Diaz de la Guardia, R | 1 |
| Roca-Ho, H | 1 |
| García-Herrero, CM | 1 |
| Lavoie, JR | 1 |
| Rosu-Myles, M | 1 |
| Gonzalez-Rey, E | 1 |
| O'Valle, F | 1 |
| Criado, G | 1 |
| Delgado, M | 1 |
| Menendez, P | 1 |
| Villanacci, V | 1 |
| Lucanto, MC | 1 |
| Barabino, A | 1 |
| Maschio, M | 1 |
| Salemme, M | 1 |
| Manenti, S | 1 |
| Lorenzi, L | 1 |
| Prakash, O | 2 |
| Medhi, B | 2 |
| Saikia, UN | 2 |
| Pandhi, P | 2 |
| Fleming, A | 1 |
| Jankowski, J | 1 |
| Goldsmith, P | 1 |
| Kim, YS | 1 |
| Kim, JS | 1 |
| Jung, HC | 1 |
| Song, IS | 1 |
| Marchetti, F | 1 |
| Caprilli, R | 1 |
| Angelucci, E | 1 |
| Cocco, A | 1 |
| Viscido, A | 1 |
| Zippi, M | 1 |
| Wang, X | 1 |
| Ouyang, Q | 1 |
| Casella, G | 1 |
| De Marco, E | 1 |
| Monti, C | 1 |
| Baldini, V | 1 |
| Yasui, K | 1 |
| Uchida, N | 1 |
| Akazawa, Y | 1 |
| Nakamura, S | 1 |
| Minami, I | 1 |
| Amano, Y | 1 |
| Yamazaki, T | 1 |
| Blam, ME | 1 |
| Stein, RB | 1 |
| Lichtenstein, GR | 1 |
| van Deventer, SJ | 1 |
| Bariol, C | 1 |
| Meagher, AP | 1 |
| Vickers, CR | 1 |
| Byrnes, DJ | 1 |
| Edwards, PD | 1 |
| Hing, M | 1 |
| Wettstein, AR | 1 |
| Field, A | 1 |
| Selby, W | 1 |
15 reviews available for thalidomide and Bowel Diseases, Inflammatory
| Article | Year |
|---|---|
Inflammatory bowel disease can reduce ovarian reserve function in women: A systematic review and meta-analysis.
Topics: Female; Humans; Infertility, Female; Inflammatory Bowel Diseases; Ovarian Reserve; Reproduction; Tha | 2023 |
[IBD and pregnancy: From conception to birth].
Topics: Cesarean Section; Colitis, Ulcerative; Crohn Disease; Delivery, Obstetric; Female; Fertilization; Fe | 2020 |
TGF-β activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases; Oligonucleoti | 2020 |
PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Evaluation, Preclinical; Humans; Inflamm | 2017 |
Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
Topics: Acitretin; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Certolizumab Pegol | 2018 |
Peripheral neuropathy and gastroenterologic disorders: an overview on an underrecognized association.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Campylobacter Infections; Celiac Disease; Child; Comor | 2018 |
[Progress in PDE4 targeted therapy for inflammatory diseases].
Topics: Aminopyridines; Aminoquinolines; Arthritis; Asthma; Benzamides; Cyclopropanes; Dermatitis; Humans; I | 2014 |
Pyoderma gangrenosum: a systematic review.
Topics: Anti-Inflammatory Agents; Arthritis; Dermatologic Agents; Diagnosis, Differential; Disease Progressi | 2014 |
Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease.
Topics: Adult; Child; Colitis, Ulcerative; Crohn Disease; Humans; Inflammatory Bowel Diseases; Remission Ind | 2015 |
The clinical implications of thalidomide in inflammatory bowel diseases.
Topics: Child; Europe; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Teratoma; Thalidomide; | 2015 |
Thalidomide for inflammatory bowel disease: Systematic review.
Topics: Humans; Immunosuppressive Agents; Induction Chemotherapy; Inflammatory Bowel Diseases; Maintenance C | 2016 |
Efficacy of conventional immunosuppressive drugs in IBD.
Topics: Azathioprine; Cyclosporine; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Mercaptop | 2004 |
The therapeutic role of thalidomide in inflammatory bowel disease.
Topics: Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Thalidomide | 2006 |
Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives.
Topics: Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Etanercept; Forecasting; Gastrointestinal | 2001 |
Small therapeutic molecules for the treatment of inflammatory bowel disease.
Topics: ADAM Proteins; ADAM17 Protein; Crohn Disease; Eicosanoids; Humans; Inflammatory Bowel Diseases; MAP | 2002 |
1 trial available for thalidomide and Bowel Diseases, Inflammatory
| Article | Year |
|---|---|
Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease.
Topics: Adult; Aged; Colitis; Colitis, Ulcerative; Colonoscopy; Crohn Disease; Female; Humans; Immunosuppres | 2002 |
18 other studies available for thalidomide and Bowel Diseases, Inflammatory
| Article | Year |
|---|---|
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf | 2023 |
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf | 2023 |
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf | 2023 |
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf | 2023 |
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf | 2023 |
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf | 2023 |
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf | 2023 |
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf | 2023 |
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf | 2023 |
Gene expression profiling in white blood cells reveals new insights into the molecular mechanisms of thalidomide in children with inflammatory bowel disease.
Topics: Adaptor Proteins, Signal Transducing; Child; Gene Expression Profiling; Humans; Inflammatory Bowel D | 2023 |
Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.
Topics: Adalimumab; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclon | 2021 |
Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.
Topics: Adult; Aged; Arthritis, Psoriatic; Cohort Studies; Etanercept; Female; France; Humans; Inflammatory | 2022 |
Thalidomide results in diminished ovarian reserve in reproductive age female IBD patients.
Topics: Adolescent; Adult; Anti-Mullerian Hormone; Azathioprine; Dose-Response Relationship, Drug; Female; H | 2017 |
Risk Factors and Outcomes of Thalidomide-induced Peripheral Neuropathy in a Pediatric Inflammatory Bowel Disease Cohort.
Topics: Adolescent; Child; Female; Humans; Inflammatory Bowel Diseases; Intercellular Adhesion Molecule-1; I | 2017 |
Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease.
Topics: Adolescent; Adult; Antibodies, Anticardiolipin; Anticoagulants; Catheterization; Catheters, Indwelli | 2013 |
Efficacy of thalidomide on trinitrobenzene sulfonate-induced colitis in young rats and its mechanism.
Topics: Animals; Colitis; Cytokines; Inflammatory Bowel Diseases; Interleukin-10; Interleukin-1beta; NF-kapp | 2014 |
Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Collagen Type II; Dextran Sulfate; Disea | 2017 |
Endoscopic and Histologic Healing in Children With Inflammatory Bowel Diseases Treated With Thalidomide.
Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Endoscopy; Female; Follow-Up Studies; | 2017 |
Effect of different doses of thalidomide in experimentally induced inflammatory bowel disease in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Disease Models, Animal; Femal | 2008 |
In vivo analysis of gut function and disease changes in a zebrafish larvae model of inflammatory bowel disease: a feasibility study.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; | 2010 |
Effect of combination of thalidomide and sulfasalazine in experimentally induced inflammatory bowel disease in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colon; Disease Models, Animal; Drug Therapy, Combi | 2011 |
The effects of thalidomide on the stimulation of NF-kappaB activity and TNF-alpha production by lipopolysaccharide in a human colonic epithelial cell line.
Topics: Cell Line; Colon; Epithelial Cells; Gene Expression Regulation; Humans; Immunosuppressive Agents; In | 2004 |
A new opportunity for thalidomide? Further randomised controlled trial are necessary.
Topics: Adolescent; Child; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Randomized Control | 2004 |
[Study the effect and mechanism of thalidomide in model of inflammatory bowed disease].
Topics: Animals; Colitis, Ulcerative; Crohn Disease; Female; Inflammatory Bowel Diseases; NF-kappa B; Oxazol | 2005 |
Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease.
Topics: Adolescent; Adult; Behcet Syndrome; C-Reactive Protein; Child; Dose-Response Relationship, Drug; Fem | 2008 |
Thalidomide in inflammatory bowel disease: too little, too soon.
Topics: Female; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Male; Thalidomide; Tumor Necr | 2002 |